Terns appoints Dr. Radhika Tripuraneni to board of directors

Terns Pharmaceuticals, Inc.

Dr. Tripuraneni appointed as Class II director and Audit Committee member effective July 26, 2022.
She is Chief Development Officer of Prothena Corporation plc with over 15 years of drug development experience.
No material transaction or arrangement exists with Dr. Tripuraneni or any related party.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Radhika Tripuraneni

Director

TERN · Terns Pharmaceuticals, Inc.

Effective: 2022-07-26
Filed: July 27, 2022, 7:59 PM ET

On July 26, 2022, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Radhika Tripuraneni, M.D., M.P.H. to serve as a Class II director until her successor is duly elected and qualified or until her earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Radhika Tripuraneni was appointed as Director at Terns Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 26, 2022, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Radhika Tripuraneni, M.D., M.P.H. to serve as a Class II director until her successor is duly elected and qualified or until her earlier death, resignation or removal.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-013212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.